Current Atherosclerosis Reports

, Volume 4, Issue 5, pp 381–385 | Cite as

Noninvasive studies of coronary and peripheral arterial blood-flow

  • Daniel Edmundowicz


Noninvasive vascular imaging may identify the high-risk, asymptomatic atherosclerotic patient who will substantially benefit from aggressive preventive therapies. Endothelium is a key player in the early stages of atherogenesis. Positron emission tomography (PET) and ultrasound-measured brachial artery vasoreactivity have emerged as potentially useful tools for the identification of endothelial dysfunction and, as such, early atherosclerosis. Both have been used successfully to demonstrate the association between endothelial dysfunction and established coronary artery disease risk factors, as well as clinically evident coronary artery disease. Abnormal coronary endothelial function recently has been associated with poor clinical outcomes in long-term follow-up studies. Given the close association between endothelial function in the coronary and peripheral circulation, there is particular promise for the validation of brachial artery vasoreactivity as a clinically useful tool. Finally, surveillance of endothelial function with these techniques may prove helpful in guiding aggressiveness of antiatherosclerotic therapy and effectiveness of new regimens.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994, 344:1383–1389.CrossRefGoogle Scholar
  2. 2.
    Sacks FM, Pfeffer MS, Moye LA, et al.: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996, 335:1001–1009.PubMedCrossRefGoogle Scholar
  3. 3.
    Shepherd J, Cobbe SM, Ford I, et al.: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995, 333:1301–1307.PubMedCrossRefGoogle Scholar
  4. 4.
    The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339:1349–1357.CrossRefGoogle Scholar
  5. 5.
    Downs JR, Clearfield M, Weis S, et al.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998, 279:1615–1622.PubMedCrossRefGoogle Scholar
  6. 6.
    Pearson TA, Laurora I, Chu H, et al.: The Lipid Treatment Assessment Project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000, 160:459–467.PubMedCrossRefGoogle Scholar
  7. 7.
    Stamler J, Wentworth D, Neaton JD: Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986, 256:2823–2828.PubMedCrossRefGoogle Scholar
  8. 8.
    Stampfer MJ, Hu FB, Manson JE, et al.: Primary prevention of coronary heart disease in women through diet and lifestyle. N Engl J Med 2000, 343:16–22.PubMedCrossRefGoogle Scholar
  9. 9.
    Pearson TA: New tools for coronary risk assessment. What are their advantages and limitation. Circulation 2002, 105:886–892.PubMedCrossRefGoogle Scholar
  10. 10.
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001, 285:2486–2497.CrossRefGoogle Scholar
  11. 11.
    Greenland P, Abrams J, Aurigemma GP, et al.: Prevention Conference V: beyond secondary prevention: identifying the high-risk patient for primary prevention: noninvasive tests of atherosclerotic burden: Writing Group III. Circulation 2000, 101:e16-e22.PubMedGoogle Scholar
  12. 12.
    Vane JR, Anggard EE, Botting RM: Regulatory functions of the vascular endothelium. N Engl J Med 1990, 323:27–36.PubMedCrossRefGoogle Scholar
  13. 13.
    McGorisk GM, Treasure CB: Endothelial dysfunction in coronary heart disease. Curr Opin Cardiol 1999, 11:341–350.CrossRefGoogle Scholar
  14. 14.
    Vogel RA: Coronary risk factors, endothelial function, and atherosclerosis: a review. Clin Cardiol 1997, 20:426–432.PubMedGoogle Scholar
  15. 15.
    Ross R: The pathogenesis of atherosclerosis—perspectives for the 1990s. Nature 1993, 362:801–809.PubMedCrossRefGoogle Scholar
  16. 16.
    Creager MA, Cooke JP, Mendelsohn ME, et al.: Impaired vasodilitation of forearm resistance vessels in hypercholesterolaemic humans. J Clin Invest 1990, 86:228–234.PubMedCrossRefGoogle Scholar
  17. 17.
    Celermajer DS, Sorenson KE, Georgakopoulos D, et al.: Passive smoking and impaired endothelium-dependant arterial dilatation in healthy young adults. N Engl J Med 1996, 334:150–154.PubMedCrossRefGoogle Scholar
  18. 18.
    Poston L, Taylor PD: Endothelium-mediated vascular function in insulin dependent diabetes mellitus. Clin Sci 1995, 88:245–255.PubMedGoogle Scholar
  19. 19.
    Bellamy MF, McDowell IF, Ramsey MW, et al.: Hyperhomocysteinemia after an oral methionine load acutely impairs endothelial function in health adults. Circulation 1998, 98:1848–1852.PubMedGoogle Scholar
  20. 20.
    Glasser SP, Selwyn AP, Ganz P: Atherosclerosis: risk factors and the vascular endothelium. Am Heart J 1996, 131:379–384.PubMedCrossRefGoogle Scholar
  21. 21.
    Vogel RA: Coronary risk factors, endothelial function, and atherosclerosis: a review. Clin Cardiol 1997, 20:426–432.PubMedCrossRefGoogle Scholar
  22. 22.
    Vogel RA, Corretti MC: Estrogens, progestins, and heart disease: can endothelial function devine the benefit? Circulation 1998, 97:1223–1226.PubMedGoogle Scholar
  23. 23.
    Flavahan NA: Atherosclerosis or lipoprotein-induced endothelial dysfunction: potential mechanisms underlying reduction in EDRF/nitric oxide activity. Circulation 1992, 85:1927–1938.PubMedGoogle Scholar
  24. 24.
    Cohen RA, Vanhoutte PM: Endothelium-dependent hyperpolarization: beyond nitric oxide and cylic GMP. Circulation 1995, 92:3337–3349.PubMedGoogle Scholar
  25. 25.
    Dimmeler S, Fleming I, Fisslthaler B, et al.: Activation of nitric oxide synthase in endothelial cells by AKT-dependent phosphorylation. Nature 1999, 399:601–605.PubMedCrossRefGoogle Scholar
  26. 26.
    Suwaidi JA, Hamasake S, Higano ST, et al.: Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000, 101:948–954.PubMedGoogle Scholar
  27. 27.
    Schachinger V, Britten MB, Zeiher AM: Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 2000, 101:1899–1906.PubMedGoogle Scholar
  28. 28.
    Hutchins GD, Schwaiger M, Rosenspire KC, et al.: Noninvasive quantification of regional blood flow in the human heart using N-13 ammonia and dynamic PET imaging. J Am Coll Cardiol 1990, 15:1031–1042.CrossRefGoogle Scholar
  29. 29.
    Beanlands RS, Muzik O, Sutor R, et al.: Noninvasive quantification of regional myocardial flow reserve in patient with coronary atherosclerosis using nitrogen-13 ammonia positron emission tomography. J Am Coll Cardiol 1995, 26:1465–1475.PubMedCrossRefGoogle Scholar
  30. 30.
    Gould KL, Martucci JP, Goldberg DI, et al.: Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease: a potential noninvasive marker of healing endothelium. Circulation 1994, 89:1530–1538.PubMedGoogle Scholar
  31. 31.
    Baller D, Notohamiprodjo G, Fleichmann U, et al.: Improvement n coronary flow reserve determined by positron emission Tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis. Circulation 1999, 99:2871–2875.PubMedGoogle Scholar
  32. 32.
    Sdringola S, Patel D, Gould KL: High prevalence of myocardial perfusion abnormalities on positron emission tomography in aysmptomatic persons with a parent or sibling with coronary artery disease. Circulation 2001, 103:496–501.PubMedGoogle Scholar
  33. 33.
    Hintze TH, Vatner SF: Reactive dilatation of large coronary arteries in conscious dogs. Circ Res 1994, 54:50–57.Google Scholar
  34. 34.
    Leeson P, Thorne S, Donald A, et al.: Non-invasive measurement of endothelial function: effect on brachial artery dilatation of graded endothelial dependent and independent stimuli. Heart 1997, 78:22–27.PubMedGoogle Scholar
  35. 35.
    Joannides R, Haefeli WE, Linder L, et al.: Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries in vivo. Circulation 1995, 91:1314–1319.PubMedGoogle Scholar
  36. 36.
    Busse R, Fleming I, Heckler M: Signal transduction in endothelium-dependent vasodilatation. Eur Heart J 1993, 14:12–19.Google Scholar
  37. 37.
    Corretti MC, Anderson TJ, Benjamin EJ, et al.: Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilatation of the brachial artery. A report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002, 39:257–265.PubMedCrossRefGoogle Scholar
  38. 38.
    Miura H, Wachtel RE, Liu Y, et al.: Flow-induced dilation of human coronary arterioles. Important role of Ca2+-activated K+ channels. Circulation 2001, 103:1992–1998.PubMedGoogle Scholar
  39. 39.
    Sun D, Huang A, Smith CJ, et al.: Enhanced release of prostaglandins contributes to flow-induced arteriolar dilatation in eNOS knockout mice. Cir Res 1999, 85:288–293.Google Scholar
  40. 40.
    Sorenson KE, Celermajer DS, Spiegelhalter DJ, et al.: Non-invasive measurement of human endothelium dependent arterial responses; accuracy and reproducibility. Br Heart J 1995, 74:247–253.Google Scholar
  41. 41.
    Stadler RW, Karl WC, Lees RS: New methods for arterial diameter measurement from B-mode images. Ultrasound Med Biol 1996, 22:25–34.PubMedCrossRefGoogle Scholar
  42. 42.
    Iiyama K, Nagano M, Yo Y, et al.: Impaired endothelial function with essential hypertension assessed by ultrasonography. Am Heart J 1996, 132:779–782.PubMedCrossRefGoogle Scholar
  43. 43.
    Vogel RA, Corretti MC, Plotnick GD: Effect of a single high-fat meal on endothelial function in healthy subject. Am J Cardiol 1997, 278:350–354.CrossRefGoogle Scholar
  44. 44.
    Lieberman EH, Gerhard MD, Uehata A, et al.: Flow-induced vasodilation of the human brachial artery is impaired in patients <40 years of age with coronary artery disease. Am J Cardiol 1996, 78:1210–1214.PubMedCrossRefGoogle Scholar
  45. 45.
    Koh KK, Cardillo C, Bui MN, et al.: Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women. Circulation 1999, 99:354–360.PubMedGoogle Scholar
  46. 46.
    Anderson TJ, Elstein E, Haber H, Charbonneau F: Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary artery disease (BANFF Study). J Am Coll Cardiol 2000, 35:60–66.PubMedCrossRefGoogle Scholar
  47. 47.
    Anderson TJ, Uehata A, Gerhard MD, et al.: Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 1995, 26:1235–1241.PubMedCrossRefGoogle Scholar
  48. 48.
    Corretti MC, Plotnick GD, Vogel RA: Technical aspects of evaluating brachial artery vasodilatation using high-frequency ultrasound. Am J Physiol 1995, 268:H1397-H1404.PubMedGoogle Scholar

Copyright information

© Current Science Inc 2002

Authors and Affiliations

  • Daniel Edmundowicz
    • 1
  1. 1.Comprehensive Heart CenterUniversity of Pittsburgh School of MedicinePittsburghUSA

Personalised recommendations